-
PDF
- Split View
-
Views
-
Cite
Cite
E H Bergene, H Nordeng, T B Rø, A Steinsbekk, Requests for new oral antibiotic prescriptions in children within 2 days: a Norwegian population-based study, Family Practice, Volume 35, Issue 6, December 2018, Pages 690–697, https://doi.org/10.1093/fampra/cmy033
- Share Icon Share
Abstract
Children commonly refuse to take antibiotics, which may induce parents to request new antibiotic prescriptions with different pharmaceutical characteristics.
To investigate prescription changes for children 0–12 years receiving oral liquid or solid antibiotic formulations and to explore the relationships between prescription changes and characteristics related to the child, prescriber and antibiotic.
A population-based registry study based on data from the Norwegian Prescription Database (NorPD) from 2004 to 2016. Antibiotic prescription changes were defined as the dispensing of subsequent antibiotics with different pharmaceutical characteristics to the same child within 2 days after initial prescriptions. Data were analysed using multivariable logistic regression and generalized estimating equations.
Requests for new prescriptions followed 3.0% of 2 691 483 initial antibiotic prescriptions for children. Young children who received solid formulations (10.9%) and certain poor-tasting antibiotics (8.6%) had the highest proportions of new prescriptions. Penicillin V was most commonly changed, while macrolides/lincosamides dominated subsequent prescriptions. In order of magnitude, the characteristics associated with requests for new prescriptions were the children’s ages, poor taste and concentration of liquids, size and shape of solids, prescribers born in recent decades, and girl patients. Reimbursed prescriptions and scored solids were associated with fewer requests.
While only 3% of the antibiotic prescriptions were changed, the preference of broad-spectrum over narrow-spectrum antibiotics for young children in this study mirrors international prescription patterns. Avoiding the costs of children’s refusal and consequent changes may thus be a motivation for choosing more preferred antibiotics.
Introduction
Antibiotics are the most commonly prescribed medicines for children in Europe (1). Worldwide, the prescription of antibiotics per child-year is highest in children 5 years and younger (0.5–3.4) and lowest in children 6–12 years (0.2–0.8) (2). Administering antibiotics to children can be challenging, and French parents reported in a survey that their child spat out at least one dose of antibiotics in 22% of the cases (3). In a recent qualitative study, parents said they battled with unwilling children and used several strategies to administer unpalatable antibiotics (4). If unable to get the child to take the medicine, parents sometimes went to the trouble of requesting a new antibiotic prescription (4,5). Such requests represent situations of negative interaction between children and parents and may reduce children’s well-being through treatment delay. Children are also at risk of increased side effects from second-line antibiotics (6). Parents spend time and money on unused antibiotics that later may be administered inappropriately (7), and health-care resources may be wasted in the form of extra time and effort by the prescriber and pharmacy. To better understand the magnitude and nature of this problem in clinical practice, studies exploring changes in antibiotic prescriptions are needed.
In a previous Danish study, 5% of <30 000 prescriptions were followed by a new prescription within 2 days for children 0–5 years (8), and a similar study found that penicillin V was changed 3.7 times more often than amoxicillin (9). The authors concluded that this could be caused by differences in palatability and found support for this in previous taste tests (10). In addition to taste, a survey of adolescents and parents of children with chronic diseases in Great Britain showed that formulation factors such as size, shape and volume as well as child’s age were correlated with children’s refusal of medicine (11). Prescriber characteristics may also be associated with use of medicines, as prescription patterns change based on a prescriber’s experience (12,13). Identifying factors related to changed prescriptions can be used to discover trends and population preferences and can be used to cause awareness and design interventions. To some extent, this can be explored in clinical practice using data from entire populations provided by national registers, such as the Norwegian Prescription Database (NorPD) (14).
The aim of this study was therefore to investigate prescriptions of oral liquid and solid antibiotic formulations changed within 2 days to antibiotics with different characteristics in children 0–12 years of age in Norway during the period from 2004 to 2016. Furthermore, associations between prescription changes and child, prescriber and antibiotic characteristics were investigated separately for solid and liquid antibiotics.
Methods
Study design and data source
This is a population-based registry study based on data on all prescriptions of oral systemic antibiotics dispensed to children from 2004 to 2016 in the NorPD. Children aged 0–12 were included to explore changes of antibiotic prescriptions across age intervals when both liquid and solid formulations were common (15). The NorPD contains information for all prescription medicines, reimbursed or not, dispensed from Norwegian pharmacies since 1st January 2004 to all individual patients living outside institutions (14).
Setting
In Norway, systemic antibiotics are available by prescription only, and a physician must be contacted to obtain a new prescription. In the community setting, antibiotics are predominantly dispensed from pharmacies to patients. Exceptions are antibiotics dispensed directly to the patient from out-of-hours primary health care centres that stock a small quantity of medications for use when pharmacies are closed (16). Antibiotics are fully paid for by the child’s parents, except for children with severe/chronic conditions (e.g. immunodeficiency, cancer, or chronic urinary tract infections), whose antibiotic prescriptions are reimbursed. Reimbursed prescriptions accounted for 3.5%–5.4% of the antibiotics prescribed for children below 12 years of age in 2012 (2).
Inclusion criteria
All systemic oral antibiotic prescriptions classified according to the Anatomical Therapeutic Chemical (ATC) Classification System as ATC-code J01 were included with the exception of the antiseptic methenamine (ATC-code J01XX05).
Changed antibiotic prescriptions
Changed antibiotic prescriptions were defined as initial prescriptions that were followed by subsequent prescriptions with a different type of antibiotic or pharmaceutical characteristic (e.g. taste, size, shape, or strength/concentration) dispensed to the same child within 2 days. This period was chosen, as changes within the first 2 days were most likely caused by challenges related to the administration of antibiotics rather than lack of clinical effect (17). Prescription change served as the dependent variable and was categorized as either ‘yes’ or ‘no’.
Characteristics
Medication characteristics
Formulations were classified as liquid (mixtures, drops, powder, and dispersible tablets) or solid (tablets and capsules).
The shapes of solid formulations were categorized as a capsule, an oval/oblong or round tablet. Scored tablets with indented lines that ease splitting were an independent category.
To compare the size of solids of different shapes, the cross-sectional area was computed using the measurement of width (w) and length (l) and the geometric formula (l − w)w + π (w/2)2. The sizes were categorized into four categories: small <20 mm2 (area of a 5-mm round tablet), medium 20–<79 mm2 (area of 10-mm round tablet), large 79–124 mm2 (area of size 1 capsule) or extra-large >124 mm2 .
Information regarding the size, shape and scoring of the solids was obtained from the Scandinavian medicinal formularies (18–20), from pillbox (21), or directly from the pharmaceutical manufacturer via personal contact. For generic medications, no longer manufactured, size information was unavailable (1.7% of the prescriptions for solid antibiotics). These were assigned to the same size category as the original matching formulation (tablet or capsule).
Antibiotics were grouped according to the ATC system and their overall prescription frequency: Penicillin V (ATC-code J01CE02), macrolides/lincosamides (ATC-code J01F), amoxicillin (ATC-code J01CA04) and others.
Poor-tasting liquids included dicloxacillin, clindamycin, trimethoprim, co-amoxicillin and penicillin V, whose scores on taste tests were so low that the likelihood for rejection by children was a concern (10,22,23).
Drops were included as a separate variable, as the concentration of antibiotic liquids is believed to influence their use in children (24).
Child characteristics
Both gender and age were included. Age was grouped as infants (0–1 years), toddlers (2–3 years), preschool children (4–5 years), school children (6–9 years) and pre-teens (10–12 years).
Prescriber characteristics
Prescribers were classified according to age, specialization and annual prescribing frequency. Age was defined by decade of birth. Specialization was categorized as general practitioner (GP) specialist, paediatrician, other specialist or no specialization. GP specialists have previously shown different antibiotic prescription patterns than non-GP specialists (25), which may influence antibiotic prescription changes. The annual prescribing frequency was grouped into quartiles due to a highly skewed distribution.
Statistical analysis
Logistic regression was used to assess the relationship between the antibiotic prescription changes and the characteristics of the child, prescriber and antibiotic. As antibiotic prescriptions could be changed several times for the same child, we used generalized estimating equations nested by children to account for possible correlations. Antibiotic prescription changes over time were analysed using univariable models, including the prescription year. Two multivariable models, including children and prescriber characteristics and either formulation characteristics (Model 1) or antibiotic groups (Model 2), were analysed separately for liquid and solid initial formulations due to the collinearity between formulation characteristics and antibiotic groups. Infants were references for liquids and pre-teens for solids due to their common use in these groups.
The results from the univariable models were reported as odds ratios (OR) with a 95% confidence interval (95% CI), while multivariable models were reported as adjusted odds ratios (adjOR) with a 95% CI. P value of <0.01 was considered statistically significant.
Several sensitivity analyses were performed to assess the robustness of the findings. First, antibiotic change was extended to 3 days after the initial prescription. Second, analyses were performed to reduce the contribution from children with more than four prescriptions per year per child (4% of all prescriptions) and from missing data by excluding prescriptions in 2004 [the year with the most missing patient IDs (26)] and children below 1 year of age, as there may have been a delay in receiving a national ID number. In addition, as Furadantin® is registered as a tablet but may be dispersed before administration, a sensitivity analysis was performed categorizing it as a liquid.
The analyses were carried out using Stata version 13.1 (StataCorp, College Station, TX).
Results
The overall dataset consisted of 2 691 483 initial prescriptions of systemic antibiotics that were dispensed to children 0–12 years between 2004 and 2016 in Norway. Of these, 21 701 prescriptions were followed by new prescriptions on the same day (Day 0), 35 703 on Day 1 and 22 697 on Day 2, totaling 80 101 changed prescriptions (3.0%).
Multiple prescriptions dispensed on the same day were excluded from the analyses as the lack of dispensing order did not allow us to identify the initial and changed antibiotic (1.6%, n = 43 769 prescriptions in 21 701 changes). Changes on Day 1–2 were therefore used for the analyses. The remaining dataset consisted of 2 670 754 initial prescriptions (1 976 238, 74% liquid and 694 516, 26% solid) dispensed to 861 991 children. The initial prescriptions were issued by 29 901 prescribers, and 41% (12 277) of these prescribers changed one or more prescriptions over the 13-year study period.
Proportions and trends of antibiotic changes on Day 1–2
On Day 1–2, 58 400 (2.2%) prescriptions were changed, of which 42 434 (2.2%) were liquid and 15 966 (2.4%) were solid. The same prescriber issued both the initial and subsequent prescriptions in 45.9% of the cases. The proportion of prescription changes increased over time for solids but not liquids (10-year OR: 1.3 for solids and 1.0 for liquids) (Fig. 1a).

Proportion of antibiotic prescription changes on Day 1–2 (%) for solid and liquid formulations for (a) year 2004–16 and (b) age 0–12 years for 2.6 million prescriptions of oral antibiotics from the Norwegian Prescription Database.
Children below the age of 7 had a higher proportion of changes following prescription of solids, whereas children above 7 years had a higher proportion of changes following liquids. Two-year-old children had the highest proportion of changes following both solids (10.9%) and liquids (2.7%) (Fig. 1b).
Among individual oral antibiotics with at least 5000 prescriptions, amoxicillin had the lowest proportion of changes for both liquids (0.8%) and solids (1.0%) (Table 1). The highest proportion of liquid prescription changes were for dicloxacillin (8.6%) and penicillin V drops (4.9%), and for solids, it was penicillin V (4.7%).
Top five individual liquid and solid antibiotics with the highest and lowest proportions of antibiotic change for prescriptions of oral antibiotics from the Norwegian Prescription Database between 2004 and 2016
Antibiotic . | Formulationa . | Initial prescriptions (n) . | Antibiotic change (%) . | Tasteb/sizea . | Brand name . |
---|---|---|---|---|---|
Liquids most commonly changed | |||||
Dicloxacillin | Suspension | 8740 | 8.6 | Poor | Diclocil® 12.5 mg/ml |
Penicillin V | Drops/solution | 19 378 | 4.9 | Poor | Weifapenin® 250 mg/ml |
Penicillin V | Drops/solution | 174 336 | 4.0 | Poor | Apocillin® 250 mg/ml |
Penicillin V | Solution | 170 714 | 3.5 | Poor | Weifapenin® 50 mg/ml |
Penicillin V | Solution | 434 782 | 3.0 | Poor | Apocillin® 50 mg/ml |
Liquids most seldom changed | |||||
Amoxicillin | Solution | 222 439 | 0.8 | Not poor | Imacillin® 50 mg/ml |
Amoxicillin | Solution | 180 306 | 0.8 | Not poor | Imacillin® 100 mg/ml |
Cefalexin | Suspension | 38 194 | 0.8 | Not poor | Keflex® 50 mg/ml |
Amoxicillin | Suspension | 7617 | 0.9 | Not poor | Amoxicillin® 100 mg/ml |
Azitromycin | Suspension | 61 249 | 1.0 | Not poor | Azitromax® 40 mg/ml |
Solids most commonly changed | |||||
Penicillin V | Oval/scored | 29 985 | 4.7 | Medium | Apocillin® 165 mg |
Erythromycin | Oval | 11 592 | 4.0 | Extra-large | Abboticin® ES 500 mg |
Erythromycin | Capsule | 68 709 | 3.8 | Large | Ery-Max® 250 mg |
Dicloxacillin | Capsule | 37 147 | 3.3 | Large | Diclocil® 250 mg |
Pivmecillinam | Round | 23 494 | 3.3 | Medium | Penomax® 200 mg |
Solids most seldom changed | |||||
Amoxicillin | Round/scored | 5982 | 1.0 | Medium | Imacillin® 250 mg |
Cefalexin | Oval/scored | 5207 | 1.2 | Large | Keflex® 500 mg |
Amoxicillin | Capsule | 10 534 | 1.2 | Large | Amoxicillin®Mylan 250 mg |
Azitromycin | Oval/scored | 9962 | 1.3 | Extra-large | Azitromax® 500 mg |
Trimethoprim | Round/scored | 11 272 | 1.3 | Medium | Trimetoprim®Orion 100 mg |
Antibiotic . | Formulationa . | Initial prescriptions (n) . | Antibiotic change (%) . | Tasteb/sizea . | Brand name . |
---|---|---|---|---|---|
Liquids most commonly changed | |||||
Dicloxacillin | Suspension | 8740 | 8.6 | Poor | Diclocil® 12.5 mg/ml |
Penicillin V | Drops/solution | 19 378 | 4.9 | Poor | Weifapenin® 250 mg/ml |
Penicillin V | Drops/solution | 174 336 | 4.0 | Poor | Apocillin® 250 mg/ml |
Penicillin V | Solution | 170 714 | 3.5 | Poor | Weifapenin® 50 mg/ml |
Penicillin V | Solution | 434 782 | 3.0 | Poor | Apocillin® 50 mg/ml |
Liquids most seldom changed | |||||
Amoxicillin | Solution | 222 439 | 0.8 | Not poor | Imacillin® 50 mg/ml |
Amoxicillin | Solution | 180 306 | 0.8 | Not poor | Imacillin® 100 mg/ml |
Cefalexin | Suspension | 38 194 | 0.8 | Not poor | Keflex® 50 mg/ml |
Amoxicillin | Suspension | 7617 | 0.9 | Not poor | Amoxicillin® 100 mg/ml |
Azitromycin | Suspension | 61 249 | 1.0 | Not poor | Azitromax® 40 mg/ml |
Solids most commonly changed | |||||
Penicillin V | Oval/scored | 29 985 | 4.7 | Medium | Apocillin® 165 mg |
Erythromycin | Oval | 11 592 | 4.0 | Extra-large | Abboticin® ES 500 mg |
Erythromycin | Capsule | 68 709 | 3.8 | Large | Ery-Max® 250 mg |
Dicloxacillin | Capsule | 37 147 | 3.3 | Large | Diclocil® 250 mg |
Pivmecillinam | Round | 23 494 | 3.3 | Medium | Penomax® 200 mg |
Solids most seldom changed | |||||
Amoxicillin | Round/scored | 5982 | 1.0 | Medium | Imacillin® 250 mg |
Cefalexin | Oval/scored | 5207 | 1.2 | Large | Keflex® 500 mg |
Amoxicillin | Capsule | 10 534 | 1.2 | Large | Amoxicillin®Mylan 250 mg |
Azitromycin | Oval/scored | 9962 | 1.3 | Extra-large | Azitromax® 500 mg |
Trimethoprim | Round/scored | 11 272 | 1.3 | Medium | Trimetoprim®Orion 100 mg |
Only antibiotics with >5000 initial prescriptions included.
aFormulation and size (medium: 20–<79 mm2, large: 79–124 mm2, extra-large: >124 mm2) based on information mainly from Scandinavian formularies (18–20).
Top five individual liquid and solid antibiotics with the highest and lowest proportions of antibiotic change for prescriptions of oral antibiotics from the Norwegian Prescription Database between 2004 and 2016
Antibiotic . | Formulationa . | Initial prescriptions (n) . | Antibiotic change (%) . | Tasteb/sizea . | Brand name . |
---|---|---|---|---|---|
Liquids most commonly changed | |||||
Dicloxacillin | Suspension | 8740 | 8.6 | Poor | Diclocil® 12.5 mg/ml |
Penicillin V | Drops/solution | 19 378 | 4.9 | Poor | Weifapenin® 250 mg/ml |
Penicillin V | Drops/solution | 174 336 | 4.0 | Poor | Apocillin® 250 mg/ml |
Penicillin V | Solution | 170 714 | 3.5 | Poor | Weifapenin® 50 mg/ml |
Penicillin V | Solution | 434 782 | 3.0 | Poor | Apocillin® 50 mg/ml |
Liquids most seldom changed | |||||
Amoxicillin | Solution | 222 439 | 0.8 | Not poor | Imacillin® 50 mg/ml |
Amoxicillin | Solution | 180 306 | 0.8 | Not poor | Imacillin® 100 mg/ml |
Cefalexin | Suspension | 38 194 | 0.8 | Not poor | Keflex® 50 mg/ml |
Amoxicillin | Suspension | 7617 | 0.9 | Not poor | Amoxicillin® 100 mg/ml |
Azitromycin | Suspension | 61 249 | 1.0 | Not poor | Azitromax® 40 mg/ml |
Solids most commonly changed | |||||
Penicillin V | Oval/scored | 29 985 | 4.7 | Medium | Apocillin® 165 mg |
Erythromycin | Oval | 11 592 | 4.0 | Extra-large | Abboticin® ES 500 mg |
Erythromycin | Capsule | 68 709 | 3.8 | Large | Ery-Max® 250 mg |
Dicloxacillin | Capsule | 37 147 | 3.3 | Large | Diclocil® 250 mg |
Pivmecillinam | Round | 23 494 | 3.3 | Medium | Penomax® 200 mg |
Solids most seldom changed | |||||
Amoxicillin | Round/scored | 5982 | 1.0 | Medium | Imacillin® 250 mg |
Cefalexin | Oval/scored | 5207 | 1.2 | Large | Keflex® 500 mg |
Amoxicillin | Capsule | 10 534 | 1.2 | Large | Amoxicillin®Mylan 250 mg |
Azitromycin | Oval/scored | 9962 | 1.3 | Extra-large | Azitromax® 500 mg |
Trimethoprim | Round/scored | 11 272 | 1.3 | Medium | Trimetoprim®Orion 100 mg |
Antibiotic . | Formulationa . | Initial prescriptions (n) . | Antibiotic change (%) . | Tasteb/sizea . | Brand name . |
---|---|---|---|---|---|
Liquids most commonly changed | |||||
Dicloxacillin | Suspension | 8740 | 8.6 | Poor | Diclocil® 12.5 mg/ml |
Penicillin V | Drops/solution | 19 378 | 4.9 | Poor | Weifapenin® 250 mg/ml |
Penicillin V | Drops/solution | 174 336 | 4.0 | Poor | Apocillin® 250 mg/ml |
Penicillin V | Solution | 170 714 | 3.5 | Poor | Weifapenin® 50 mg/ml |
Penicillin V | Solution | 434 782 | 3.0 | Poor | Apocillin® 50 mg/ml |
Liquids most seldom changed | |||||
Amoxicillin | Solution | 222 439 | 0.8 | Not poor | Imacillin® 50 mg/ml |
Amoxicillin | Solution | 180 306 | 0.8 | Not poor | Imacillin® 100 mg/ml |
Cefalexin | Suspension | 38 194 | 0.8 | Not poor | Keflex® 50 mg/ml |
Amoxicillin | Suspension | 7617 | 0.9 | Not poor | Amoxicillin® 100 mg/ml |
Azitromycin | Suspension | 61 249 | 1.0 | Not poor | Azitromax® 40 mg/ml |
Solids most commonly changed | |||||
Penicillin V | Oval/scored | 29 985 | 4.7 | Medium | Apocillin® 165 mg |
Erythromycin | Oval | 11 592 | 4.0 | Extra-large | Abboticin® ES 500 mg |
Erythromycin | Capsule | 68 709 | 3.8 | Large | Ery-Max® 250 mg |
Dicloxacillin | Capsule | 37 147 | 3.3 | Large | Diclocil® 250 mg |
Pivmecillinam | Round | 23 494 | 3.3 | Medium | Penomax® 200 mg |
Solids most seldom changed | |||||
Amoxicillin | Round/scored | 5982 | 1.0 | Medium | Imacillin® 250 mg |
Cefalexin | Oval/scored | 5207 | 1.2 | Large | Keflex® 500 mg |
Amoxicillin | Capsule | 10 534 | 1.2 | Large | Amoxicillin®Mylan 250 mg |
Azitromycin | Oval/scored | 9962 | 1.3 | Extra-large | Azitromax® 500 mg |
Trimethoprim | Round/scored | 11 272 | 1.3 | Medium | Trimetoprim®Orion 100 mg |
Only antibiotics with >5000 initial prescriptions included.
aFormulation and size (medium: 20–<79 mm2, large: 79–124 mm2, extra-large: >124 mm2) based on information mainly from Scandinavian formularies (18–20).
Characteristics associated with requests for new prescriptions following liquid antibiotics
In the multivariable models, changes associated with liquid antibiotic prescriptions were (in decreasing magnitude) as follows: antibiotic taste, reimbursed prescriptions, drops, children’s age, prescriber’s birth decade and number of prescriptions issued per year, and gender (Table 2).
Liquids: characteristics associated with liquid antibiotic formulations that were changed to a prescription with a different antibiotic or pharmaceutical characteristic from the Norwegian Prescription Database between 2004 and 2016
Liquid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP), n = 1 976 238 . | Subsequent prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Liquid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Infant 0–1 years | 623 791 | 12 561 (2.0) | Reference | Reference | Reference |
Toddler 2–3 years | 640 816 | 16 277 (2.5) | 1.27 (1.24–1.30) | 1.27 (1.24–1.30) | 1.26 (1.23–1.29) |
Preschool 4–5 years | 396 021 | 7335 (1.9) | 0.93 (0.90–0.95) | 0.91 (0.88–0.93) | 0.89 (0.87–0.92) |
School 6–9 years | 274 862 | 5359 (2.0) | 0.98 (0.95–1.02) | 1.01 (0.97–1.04) | 0.99 (0.96–1.02) |
Pre-teen 10–12 years | 40 748 | 902 (2.2) | 1.13 (1.06–1.22) | 1.22 (1.14–1.31) | 1.17 (1.09–1.26) |
Girl | 962 148 | 20 926 (2.2) | 1.03 (1.01–1.05) | 1.02 (1.00–1.05) | 1.07 (1.05–1.09) |
Reimbursed AB | 83 825 | 850 (1.0) | 0.46 (0.43–0.50) | 0.53 (0.49–0.58) | 0.66 (0.61–0.72) |
Prescriber | |||||
Specialist | |||||
None | 974 765 | 23 082 (2.4) | Reference | Reference | Reference |
GP | 815 927 | 16 405 (2.0) | 0.85 (0.83–0.86) | 0.97 (0.94–0.99) | 0.98 (0.96–1.01) |
Paediatrician | 98 565 | 1449 (1.5) | 0.65 (0.61–0.69) | 0.92 (0.86–0.97) | 0.92 (0.87–0.98) |
Other | 86 981 | 1498 (1.7) | 0.73 (0.69–0.77) | 0.92 (0.87–0.97) | 0.96 (0.91–1.01) |
Birth year | |||||
Before 1950 | 175 637 | 3215 (1.8) | Reference | Reference | Reference |
1950–59 | 499 770 | 9300 (1.9) | 1.01 (0.97–1.06) | 1.02 (0.98–1.06) | 1.02 (0.98–1.07) |
1960–69 | 502 622 | 10 431 (2.1) | 1.13 (1.09–1.18) | 1.07 (1.03–1.12) | 1.08 (1.03–1.13) |
1970–79 | 572 659 | 13 565 (2.4) | 1.29 (1.24–1.35) | 1.11 (1.07–1.16) | 1.13 (1.08–1.18) |
After 1980 | 224 634 | 5903 (2.2) | 1.44 (1.37–1.50) | 1.20 (1.14–1.26) | 1.19 (1.13–1.25) |
Female prescriber | 729 961 | 16 156 (2.2) | 1.05 (1.03–1.07) | 0.97 (0.95–0.99) | 0.98 (0.96–1.00) |
AB prescriptions per year (quartiles) | |||||
<23 | 461 948 | 10 308 (2.2) | Reference | Reference | Reference |
24–42 | 489 763 | 11 095 (2.3) | 1.01 (0.99–1.04) | 1.06 (1.03–1.09) | 1.07 (1.04–1.10) |
43–73 | 511 290 | 10 056 (2.2) | 0.97 (0.94–0.99) | 1.08 (1.05–1.11) | 1.09 (1.06–1.12) |
>73 | 513 237 | 9975 (1.9) | 0.87 (0.84–0.89) | 1.04 (1.01–1.07) | 1.07 (1.04–1.10) |
Liquid antibiotic | |||||
Poor taste | 968 756 | 29 954 (3.1) | 2.60 (2.55–2.66) | 2.35 (2.30–2.41) | |
Drops | 194 192 | 7986 (4.2) | 2.17 (2.12–2.23) | 1.45 (1.41–1.49) | |
Antibiotics | |||||
Amoxicillin | 412 145 | 3229 (0.8) | Reference | Reference | |
Dicloxacillin | 8740 | 756 (8.7) | 12.4 (11.4–13.5) | 12.3 (11.3–13.4) | |
Penicillin V | 799 380 | 26 825 (3.4) | 4.55 (4.38–4.73) | 4.52 (4.35–4.70) | |
Clarithromycin | 55 237 | 938 (1.7) | 2.22 (2.06–2.40) | 2.34 (2.17–2.53) | |
Erythromycin | 358 940 | 6037 (1.7) | 2.21 (2.12–2.31) | 2.24 (2.14–2.34) | |
Clindamycin | 49 524 | 821 (1.7) | 2.16 (1.99–2.34) | 2.20 (2.03–2.39) | |
Trim-sulpha | 79 725 | 1271 (1.6) | 2.09 (1.95–2.24) | 2.22 (2.07–2.38) | |
Trimethoprim | 107 010 | 1475 (1.4) | 1.82 (1.70–1.94) | 1.93 (1.80–2.06) | |
Azitromycin | 61 249 | 614 (1.0) | 1.31 (1.20–1.44) | 1.41 (1.28–1.55) | |
Cefalexin | 38 194 | 324 (0.9) | 1.04 (0.92–1.18) | 1.09 (0.96–1.24) |
Liquid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP), n = 1 976 238 . | Subsequent prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Liquid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Infant 0–1 years | 623 791 | 12 561 (2.0) | Reference | Reference | Reference |
Toddler 2–3 years | 640 816 | 16 277 (2.5) | 1.27 (1.24–1.30) | 1.27 (1.24–1.30) | 1.26 (1.23–1.29) |
Preschool 4–5 years | 396 021 | 7335 (1.9) | 0.93 (0.90–0.95) | 0.91 (0.88–0.93) | 0.89 (0.87–0.92) |
School 6–9 years | 274 862 | 5359 (2.0) | 0.98 (0.95–1.02) | 1.01 (0.97–1.04) | 0.99 (0.96–1.02) |
Pre-teen 10–12 years | 40 748 | 902 (2.2) | 1.13 (1.06–1.22) | 1.22 (1.14–1.31) | 1.17 (1.09–1.26) |
Girl | 962 148 | 20 926 (2.2) | 1.03 (1.01–1.05) | 1.02 (1.00–1.05) | 1.07 (1.05–1.09) |
Reimbursed AB | 83 825 | 850 (1.0) | 0.46 (0.43–0.50) | 0.53 (0.49–0.58) | 0.66 (0.61–0.72) |
Prescriber | |||||
Specialist | |||||
None | 974 765 | 23 082 (2.4) | Reference | Reference | Reference |
GP | 815 927 | 16 405 (2.0) | 0.85 (0.83–0.86) | 0.97 (0.94–0.99) | 0.98 (0.96–1.01) |
Paediatrician | 98 565 | 1449 (1.5) | 0.65 (0.61–0.69) | 0.92 (0.86–0.97) | 0.92 (0.87–0.98) |
Other | 86 981 | 1498 (1.7) | 0.73 (0.69–0.77) | 0.92 (0.87–0.97) | 0.96 (0.91–1.01) |
Birth year | |||||
Before 1950 | 175 637 | 3215 (1.8) | Reference | Reference | Reference |
1950–59 | 499 770 | 9300 (1.9) | 1.01 (0.97–1.06) | 1.02 (0.98–1.06) | 1.02 (0.98–1.07) |
1960–69 | 502 622 | 10 431 (2.1) | 1.13 (1.09–1.18) | 1.07 (1.03–1.12) | 1.08 (1.03–1.13) |
1970–79 | 572 659 | 13 565 (2.4) | 1.29 (1.24–1.35) | 1.11 (1.07–1.16) | 1.13 (1.08–1.18) |
After 1980 | 224 634 | 5903 (2.2) | 1.44 (1.37–1.50) | 1.20 (1.14–1.26) | 1.19 (1.13–1.25) |
Female prescriber | 729 961 | 16 156 (2.2) | 1.05 (1.03–1.07) | 0.97 (0.95–0.99) | 0.98 (0.96–1.00) |
AB prescriptions per year (quartiles) | |||||
<23 | 461 948 | 10 308 (2.2) | Reference | Reference | Reference |
24–42 | 489 763 | 11 095 (2.3) | 1.01 (0.99–1.04) | 1.06 (1.03–1.09) | 1.07 (1.04–1.10) |
43–73 | 511 290 | 10 056 (2.2) | 0.97 (0.94–0.99) | 1.08 (1.05–1.11) | 1.09 (1.06–1.12) |
>73 | 513 237 | 9975 (1.9) | 0.87 (0.84–0.89) | 1.04 (1.01–1.07) | 1.07 (1.04–1.10) |
Liquid antibiotic | |||||
Poor taste | 968 756 | 29 954 (3.1) | 2.60 (2.55–2.66) | 2.35 (2.30–2.41) | |
Drops | 194 192 | 7986 (4.2) | 2.17 (2.12–2.23) | 1.45 (1.41–1.49) | |
Antibiotics | |||||
Amoxicillin | 412 145 | 3229 (0.8) | Reference | Reference | |
Dicloxacillin | 8740 | 756 (8.7) | 12.4 (11.4–13.5) | 12.3 (11.3–13.4) | |
Penicillin V | 799 380 | 26 825 (3.4) | 4.55 (4.38–4.73) | 4.52 (4.35–4.70) | |
Clarithromycin | 55 237 | 938 (1.7) | 2.22 (2.06–2.40) | 2.34 (2.17–2.53) | |
Erythromycin | 358 940 | 6037 (1.7) | 2.21 (2.12–2.31) | 2.24 (2.14–2.34) | |
Clindamycin | 49 524 | 821 (1.7) | 2.16 (1.99–2.34) | 2.20 (2.03–2.39) | |
Trim-sulpha | 79 725 | 1271 (1.6) | 2.09 (1.95–2.24) | 2.22 (2.07–2.38) | |
Trimethoprim | 107 010 | 1475 (1.4) | 1.82 (1.70–1.94) | 1.93 (1.80–2.06) | |
Azitromycin | 61 249 | 614 (1.0) | 1.31 (1.20–1.44) | 1.41 (1.28–1.55) | |
Cefalexin | 38 194 | 324 (0.9) | 1.04 (0.92–1.18) | 1.09 (0.96–1.24) |
Multivariable models were also adjusted for the year the AB was dispensed. Only antibiotics with >5000 prescriptions are listed. Bold indicates P < 0.01.
AB, antibiotic; adjOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
Liquids: characteristics associated with liquid antibiotic formulations that were changed to a prescription with a different antibiotic or pharmaceutical characteristic from the Norwegian Prescription Database between 2004 and 2016
Liquid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP), n = 1 976 238 . | Subsequent prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Liquid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Infant 0–1 years | 623 791 | 12 561 (2.0) | Reference | Reference | Reference |
Toddler 2–3 years | 640 816 | 16 277 (2.5) | 1.27 (1.24–1.30) | 1.27 (1.24–1.30) | 1.26 (1.23–1.29) |
Preschool 4–5 years | 396 021 | 7335 (1.9) | 0.93 (0.90–0.95) | 0.91 (0.88–0.93) | 0.89 (0.87–0.92) |
School 6–9 years | 274 862 | 5359 (2.0) | 0.98 (0.95–1.02) | 1.01 (0.97–1.04) | 0.99 (0.96–1.02) |
Pre-teen 10–12 years | 40 748 | 902 (2.2) | 1.13 (1.06–1.22) | 1.22 (1.14–1.31) | 1.17 (1.09–1.26) |
Girl | 962 148 | 20 926 (2.2) | 1.03 (1.01–1.05) | 1.02 (1.00–1.05) | 1.07 (1.05–1.09) |
Reimbursed AB | 83 825 | 850 (1.0) | 0.46 (0.43–0.50) | 0.53 (0.49–0.58) | 0.66 (0.61–0.72) |
Prescriber | |||||
Specialist | |||||
None | 974 765 | 23 082 (2.4) | Reference | Reference | Reference |
GP | 815 927 | 16 405 (2.0) | 0.85 (0.83–0.86) | 0.97 (0.94–0.99) | 0.98 (0.96–1.01) |
Paediatrician | 98 565 | 1449 (1.5) | 0.65 (0.61–0.69) | 0.92 (0.86–0.97) | 0.92 (0.87–0.98) |
Other | 86 981 | 1498 (1.7) | 0.73 (0.69–0.77) | 0.92 (0.87–0.97) | 0.96 (0.91–1.01) |
Birth year | |||||
Before 1950 | 175 637 | 3215 (1.8) | Reference | Reference | Reference |
1950–59 | 499 770 | 9300 (1.9) | 1.01 (0.97–1.06) | 1.02 (0.98–1.06) | 1.02 (0.98–1.07) |
1960–69 | 502 622 | 10 431 (2.1) | 1.13 (1.09–1.18) | 1.07 (1.03–1.12) | 1.08 (1.03–1.13) |
1970–79 | 572 659 | 13 565 (2.4) | 1.29 (1.24–1.35) | 1.11 (1.07–1.16) | 1.13 (1.08–1.18) |
After 1980 | 224 634 | 5903 (2.2) | 1.44 (1.37–1.50) | 1.20 (1.14–1.26) | 1.19 (1.13–1.25) |
Female prescriber | 729 961 | 16 156 (2.2) | 1.05 (1.03–1.07) | 0.97 (0.95–0.99) | 0.98 (0.96–1.00) |
AB prescriptions per year (quartiles) | |||||
<23 | 461 948 | 10 308 (2.2) | Reference | Reference | Reference |
24–42 | 489 763 | 11 095 (2.3) | 1.01 (0.99–1.04) | 1.06 (1.03–1.09) | 1.07 (1.04–1.10) |
43–73 | 511 290 | 10 056 (2.2) | 0.97 (0.94–0.99) | 1.08 (1.05–1.11) | 1.09 (1.06–1.12) |
>73 | 513 237 | 9975 (1.9) | 0.87 (0.84–0.89) | 1.04 (1.01–1.07) | 1.07 (1.04–1.10) |
Liquid antibiotic | |||||
Poor taste | 968 756 | 29 954 (3.1) | 2.60 (2.55–2.66) | 2.35 (2.30–2.41) | |
Drops | 194 192 | 7986 (4.2) | 2.17 (2.12–2.23) | 1.45 (1.41–1.49) | |
Antibiotics | |||||
Amoxicillin | 412 145 | 3229 (0.8) | Reference | Reference | |
Dicloxacillin | 8740 | 756 (8.7) | 12.4 (11.4–13.5) | 12.3 (11.3–13.4) | |
Penicillin V | 799 380 | 26 825 (3.4) | 4.55 (4.38–4.73) | 4.52 (4.35–4.70) | |
Clarithromycin | 55 237 | 938 (1.7) | 2.22 (2.06–2.40) | 2.34 (2.17–2.53) | |
Erythromycin | 358 940 | 6037 (1.7) | 2.21 (2.12–2.31) | 2.24 (2.14–2.34) | |
Clindamycin | 49 524 | 821 (1.7) | 2.16 (1.99–2.34) | 2.20 (2.03–2.39) | |
Trim-sulpha | 79 725 | 1271 (1.6) | 2.09 (1.95–2.24) | 2.22 (2.07–2.38) | |
Trimethoprim | 107 010 | 1475 (1.4) | 1.82 (1.70–1.94) | 1.93 (1.80–2.06) | |
Azitromycin | 61 249 | 614 (1.0) | 1.31 (1.20–1.44) | 1.41 (1.28–1.55) | |
Cefalexin | 38 194 | 324 (0.9) | 1.04 (0.92–1.18) | 1.09 (0.96–1.24) |
Liquid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP), n = 1 976 238 . | Subsequent prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Liquid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Infant 0–1 years | 623 791 | 12 561 (2.0) | Reference | Reference | Reference |
Toddler 2–3 years | 640 816 | 16 277 (2.5) | 1.27 (1.24–1.30) | 1.27 (1.24–1.30) | 1.26 (1.23–1.29) |
Preschool 4–5 years | 396 021 | 7335 (1.9) | 0.93 (0.90–0.95) | 0.91 (0.88–0.93) | 0.89 (0.87–0.92) |
School 6–9 years | 274 862 | 5359 (2.0) | 0.98 (0.95–1.02) | 1.01 (0.97–1.04) | 0.99 (0.96–1.02) |
Pre-teen 10–12 years | 40 748 | 902 (2.2) | 1.13 (1.06–1.22) | 1.22 (1.14–1.31) | 1.17 (1.09–1.26) |
Girl | 962 148 | 20 926 (2.2) | 1.03 (1.01–1.05) | 1.02 (1.00–1.05) | 1.07 (1.05–1.09) |
Reimbursed AB | 83 825 | 850 (1.0) | 0.46 (0.43–0.50) | 0.53 (0.49–0.58) | 0.66 (0.61–0.72) |
Prescriber | |||||
Specialist | |||||
None | 974 765 | 23 082 (2.4) | Reference | Reference | Reference |
GP | 815 927 | 16 405 (2.0) | 0.85 (0.83–0.86) | 0.97 (0.94–0.99) | 0.98 (0.96–1.01) |
Paediatrician | 98 565 | 1449 (1.5) | 0.65 (0.61–0.69) | 0.92 (0.86–0.97) | 0.92 (0.87–0.98) |
Other | 86 981 | 1498 (1.7) | 0.73 (0.69–0.77) | 0.92 (0.87–0.97) | 0.96 (0.91–1.01) |
Birth year | |||||
Before 1950 | 175 637 | 3215 (1.8) | Reference | Reference | Reference |
1950–59 | 499 770 | 9300 (1.9) | 1.01 (0.97–1.06) | 1.02 (0.98–1.06) | 1.02 (0.98–1.07) |
1960–69 | 502 622 | 10 431 (2.1) | 1.13 (1.09–1.18) | 1.07 (1.03–1.12) | 1.08 (1.03–1.13) |
1970–79 | 572 659 | 13 565 (2.4) | 1.29 (1.24–1.35) | 1.11 (1.07–1.16) | 1.13 (1.08–1.18) |
After 1980 | 224 634 | 5903 (2.2) | 1.44 (1.37–1.50) | 1.20 (1.14–1.26) | 1.19 (1.13–1.25) |
Female prescriber | 729 961 | 16 156 (2.2) | 1.05 (1.03–1.07) | 0.97 (0.95–0.99) | 0.98 (0.96–1.00) |
AB prescriptions per year (quartiles) | |||||
<23 | 461 948 | 10 308 (2.2) | Reference | Reference | Reference |
24–42 | 489 763 | 11 095 (2.3) | 1.01 (0.99–1.04) | 1.06 (1.03–1.09) | 1.07 (1.04–1.10) |
43–73 | 511 290 | 10 056 (2.2) | 0.97 (0.94–0.99) | 1.08 (1.05–1.11) | 1.09 (1.06–1.12) |
>73 | 513 237 | 9975 (1.9) | 0.87 (0.84–0.89) | 1.04 (1.01–1.07) | 1.07 (1.04–1.10) |
Liquid antibiotic | |||||
Poor taste | 968 756 | 29 954 (3.1) | 2.60 (2.55–2.66) | 2.35 (2.30–2.41) | |
Drops | 194 192 | 7986 (4.2) | 2.17 (2.12–2.23) | 1.45 (1.41–1.49) | |
Antibiotics | |||||
Amoxicillin | 412 145 | 3229 (0.8) | Reference | Reference | |
Dicloxacillin | 8740 | 756 (8.7) | 12.4 (11.4–13.5) | 12.3 (11.3–13.4) | |
Penicillin V | 799 380 | 26 825 (3.4) | 4.55 (4.38–4.73) | 4.52 (4.35–4.70) | |
Clarithromycin | 55 237 | 938 (1.7) | 2.22 (2.06–2.40) | 2.34 (2.17–2.53) | |
Erythromycin | 358 940 | 6037 (1.7) | 2.21 (2.12–2.31) | 2.24 (2.14–2.34) | |
Clindamycin | 49 524 | 821 (1.7) | 2.16 (1.99–2.34) | 2.20 (2.03–2.39) | |
Trim-sulpha | 79 725 | 1271 (1.6) | 2.09 (1.95–2.24) | 2.22 (2.07–2.38) | |
Trimethoprim | 107 010 | 1475 (1.4) | 1.82 (1.70–1.94) | 1.93 (1.80–2.06) | |
Azitromycin | 61 249 | 614 (1.0) | 1.31 (1.20–1.44) | 1.41 (1.28–1.55) | |
Cefalexin | 38 194 | 324 (0.9) | 1.04 (0.92–1.18) | 1.09 (0.96–1.24) |
Multivariable models were also adjusted for the year the AB was dispensed. Only antibiotics with >5000 prescriptions are listed. Bold indicates P < 0.01.
AB, antibiotic; adjOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
Compared with infants (0–1 years), prescriptions dispensed to toddlers (2–3 years) had the strongest association with prescription changes (adjOR: 1.3) followed by pre-teens (adjOR: 1.2) (Table 2). Reimbursed prescriptions dispensed to children with a chronic disease were least associated with changes (adjOR: 0.7). Girls had significantly higher odds than boys for prescription changes (adjOR: 1.07).
Younger prescribers were more strongly associated with changes compared with those born before 1950 (born after 1980, adjOR: 1.2).
The variables most strongly associated with a high number of prescription changes were antibiotics with a poor taste (adjOR: 2.4) and drops (adjOR: 1.5) (Table 2).
Characteristics associated with requests for new prescriptions following solid antibiotics
The prescriber characteristics associated with solid antibiotic prescription changes were quite similar to the prescriber characteristics of liquid antibiotic prescription changes; however, the difference in the association of changes between age groups was much greater for solids than liquids (Table 3).
Solids: characteristics associated with solid antibiotic formulations that were changed to a prescription with a different antibiotic or pharmaceutical characteristic from the Norwegian Prescription Database (NorPD) between 2004 and 2016
Solid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP) n = 694 516 . | Re-prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Solid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Pre-teen 10–12 years | 272 388 | 4156 (1.5) | Reference | Reference | Reference |
School 6–9 years | 313 042 | 6046 (1.9) | 1.28 (1.23–1.33) | 1.40 (1.35–1.46) | 1.38 (1.33–1.44) |
Preschool 4–5 years | 74 159 | 2856 (3.9) | 2.61 (2.49–2.74) | 3.06 (2.90–3.22) | 3.13 (2.98–3.29) |
Toddler 2–3 years | 26 107 | 2275 (8.7) | 6.25 (5.92–6.59) | 7.86 (7.43–8.33) | 8.25 (7.80–8.73) |
Infant 0–1 years | 8820 | 633 (7.2) | 5.18 (4.74–5.67) | 7.87 (7.16–8.66) | 8.81 (7.99–9.71) |
Girl | 380 566 | 8790 (2.3) | 1.01 (0.98–1.05) | 1.06 (1.03–1.10) | 1.06 (1.03–1.10) |
Reimbursed AB | 35 778 | 510 (1.4) | 0.62 (0.57–0.68) | 0.57 (0.52–0.63) | 0.68 (0.61–0.76) |
Prescriber | |||||
Specialist | |||||
None (ref) | 331 810 | 7935 (2.4) | Reference | Reference | Reference |
GP | 306 018 | 6980 (2.3) | 0.95 (0.92–0.99) | 1.05 (1.01–1.10) | 1.04 (1.00–1.08) |
Paediatrician | 26 286 | 524 (2.0) | 0.86 (0.79–0.94) | 0.96 (0.87–1.06) | 1.00 (0.91–1.11) |
Other | 30 402 | 527 (1.7) | 0.73 (0.66–0.79) | 0.84 (0.77–0.92) | 0.90 (0.82–0.99) |
Birth year | |||||
Before 1950 | 67 823 | 1291 (1.9) | Reference | Reference | Reference |
1950–59 | 192 050 | 4023 (2.1) | 1.10 (1.03–1.17) | 1.02 (0.96–1.09) | 1.02 (0.96–1.09) |
1960–69 | 172 782 | 3912 (2.3) | 1.19 (1.12–1.27) | 1.09 (1.02–1.16) | 1.08 (1.01–1.15) |
1970–79 | 184 484 | 4549 (2.5) | 1.30 (1.22–1.38) | 1.16 (1.09–1.25) | 1.15 (1.08–1.24) |
After 1980 | 77 011 | 2186 (2.8) | 1.49 (1.39–1.60) | 1.26 (1.16–1.37) | 1.25 (1.15–1.36) |
Female prescriber | 240 884 | 5660 (2.3) | 1.04 (1.00–1.07) | 0.98 (0.95–1.02) | 0.97 (0.94–1.01) |
AB Prescriptions per year (quart) | |||||
<23 | 208 436 | 4587 (2.2) | Reference | Reference | Reference |
24–42 | 174 434 | 4139 (2.4) | 1.08 (1.04–1.13) | 1.10 (1.05–1.15) | 1.08 (1.04–1.13) |
43–73 | 166 187 | 3965 (2.4) | 1.09 (1.04–1.14) | 1.15 (1.10–1.20) | 1.13 (1.08–1.19) |
>73 | 145 459 | 3275 (2.3) | 1.03 (0.98–1.08) | 1.14 (1.08–1.19) | 1.13 (1.07–1.18) |
Solid antibiotic | |||||
Shape | |||||
Round | 137 849 | 3023 (2.2) | Reference | Reference | |
Oval | 399 566 | 8090 (2.0) | 0.91 (0.88–0.95) | 1.32 (1.25–1.39) | |
Capsule | 157 101 | 4853 (3.1) | 1.40 (1.34–1.47) | 1.50 (1.41–1.60) | |
Scored | 418 047 | 7849 (1.9) | 0.63 (0.62–0.66) | 0.64 (0.60–0.67) | |
Size | |||||
20–<79 mm2 | 360 892 | 7898 (2.2) | Reference | Reference | |
79–124 mm2 | 281 419 | 6887 (2.4) | 1.12 (1.08–1.16) | 1.06 (1.00–1.11) | |
>124 mm2 | 52 205 | 1181 (2.3) | 1.04 (0.97–1.10) | 1.19 (1.10–1.28) | |
Antibiotic | |||||
Amoxicillin | 26 429 | 321 (1.2) | Reference | Reference | |
Erythromycin | 80 309 | 3102 (3.9) | 3.25 (2.90–3.65) | 3.92 (3.49–4.42) | |
Dicloxacillin | 55 097 | 1644 (3.0) | 2.50 (2.22–2.82) | 2.22 (1.96–2.51) | |
Clarithromycin | 8971 | 169 (1.9) | 1.56 (1.29–1.88) | 2.10 (1.74–2.54) | |
Pivmecillinam | 56 993 | 1780 (3.1) | 2.63 (2.33–2.96) | 1.83 (1.62–2.08) | |
Clindamycin | 17 996 | 384 (2.1) | 1.76 (1.52–2.05) | 1.76 (1.51–2.05) | |
Penicillin V | 355 262 | 7142 (2.0) | 1.67 (1.49–1.87) | 1.50 (1.34–1.68) | |
Azitromycin | 9969 | 134 (1.3) | 1.12 (0.91–1.37) | 1.34 (1.09–1.64) | |
Doxycycline | 5000 | 65 (1.3) | 1.06 (0.81–1.38) | 1.33 (1.01–1.75) | |
Trim-sulpha | 14 964 | 210 (1.4) | 1.18 (0.99–1.41) | 1.26 (1.05–1.51) | |
Trimethoprim | 22 510 | 305 (1.4) | 1.13 (0.97–1.32) | 1.17 (0.99–1.37) | |
Cefalexin | 6 064 | 71 (1.2) | 0.97 (0.75–1.26) | 1.11 (0.86–1.44) | |
Nitrofurantoin | 24 499 | 435 (1.8) | 1.49 (1.28–1.72) | 0.61 (0.52–0.72) |
Solid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP) n = 694 516 . | Re-prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Solid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Pre-teen 10–12 years | 272 388 | 4156 (1.5) | Reference | Reference | Reference |
School 6–9 years | 313 042 | 6046 (1.9) | 1.28 (1.23–1.33) | 1.40 (1.35–1.46) | 1.38 (1.33–1.44) |
Preschool 4–5 years | 74 159 | 2856 (3.9) | 2.61 (2.49–2.74) | 3.06 (2.90–3.22) | 3.13 (2.98–3.29) |
Toddler 2–3 years | 26 107 | 2275 (8.7) | 6.25 (5.92–6.59) | 7.86 (7.43–8.33) | 8.25 (7.80–8.73) |
Infant 0–1 years | 8820 | 633 (7.2) | 5.18 (4.74–5.67) | 7.87 (7.16–8.66) | 8.81 (7.99–9.71) |
Girl | 380 566 | 8790 (2.3) | 1.01 (0.98–1.05) | 1.06 (1.03–1.10) | 1.06 (1.03–1.10) |
Reimbursed AB | 35 778 | 510 (1.4) | 0.62 (0.57–0.68) | 0.57 (0.52–0.63) | 0.68 (0.61–0.76) |
Prescriber | |||||
Specialist | |||||
None (ref) | 331 810 | 7935 (2.4) | Reference | Reference | Reference |
GP | 306 018 | 6980 (2.3) | 0.95 (0.92–0.99) | 1.05 (1.01–1.10) | 1.04 (1.00–1.08) |
Paediatrician | 26 286 | 524 (2.0) | 0.86 (0.79–0.94) | 0.96 (0.87–1.06) | 1.00 (0.91–1.11) |
Other | 30 402 | 527 (1.7) | 0.73 (0.66–0.79) | 0.84 (0.77–0.92) | 0.90 (0.82–0.99) |
Birth year | |||||
Before 1950 | 67 823 | 1291 (1.9) | Reference | Reference | Reference |
1950–59 | 192 050 | 4023 (2.1) | 1.10 (1.03–1.17) | 1.02 (0.96–1.09) | 1.02 (0.96–1.09) |
1960–69 | 172 782 | 3912 (2.3) | 1.19 (1.12–1.27) | 1.09 (1.02–1.16) | 1.08 (1.01–1.15) |
1970–79 | 184 484 | 4549 (2.5) | 1.30 (1.22–1.38) | 1.16 (1.09–1.25) | 1.15 (1.08–1.24) |
After 1980 | 77 011 | 2186 (2.8) | 1.49 (1.39–1.60) | 1.26 (1.16–1.37) | 1.25 (1.15–1.36) |
Female prescriber | 240 884 | 5660 (2.3) | 1.04 (1.00–1.07) | 0.98 (0.95–1.02) | 0.97 (0.94–1.01) |
AB Prescriptions per year (quart) | |||||
<23 | 208 436 | 4587 (2.2) | Reference | Reference | Reference |
24–42 | 174 434 | 4139 (2.4) | 1.08 (1.04–1.13) | 1.10 (1.05–1.15) | 1.08 (1.04–1.13) |
43–73 | 166 187 | 3965 (2.4) | 1.09 (1.04–1.14) | 1.15 (1.10–1.20) | 1.13 (1.08–1.19) |
>73 | 145 459 | 3275 (2.3) | 1.03 (0.98–1.08) | 1.14 (1.08–1.19) | 1.13 (1.07–1.18) |
Solid antibiotic | |||||
Shape | |||||
Round | 137 849 | 3023 (2.2) | Reference | Reference | |
Oval | 399 566 | 8090 (2.0) | 0.91 (0.88–0.95) | 1.32 (1.25–1.39) | |
Capsule | 157 101 | 4853 (3.1) | 1.40 (1.34–1.47) | 1.50 (1.41–1.60) | |
Scored | 418 047 | 7849 (1.9) | 0.63 (0.62–0.66) | 0.64 (0.60–0.67) | |
Size | |||||
20–<79 mm2 | 360 892 | 7898 (2.2) | Reference | Reference | |
79–124 mm2 | 281 419 | 6887 (2.4) | 1.12 (1.08–1.16) | 1.06 (1.00–1.11) | |
>124 mm2 | 52 205 | 1181 (2.3) | 1.04 (0.97–1.10) | 1.19 (1.10–1.28) | |
Antibiotic | |||||
Amoxicillin | 26 429 | 321 (1.2) | Reference | Reference | |
Erythromycin | 80 309 | 3102 (3.9) | 3.25 (2.90–3.65) | 3.92 (3.49–4.42) | |
Dicloxacillin | 55 097 | 1644 (3.0) | 2.50 (2.22–2.82) | 2.22 (1.96–2.51) | |
Clarithromycin | 8971 | 169 (1.9) | 1.56 (1.29–1.88) | 2.10 (1.74–2.54) | |
Pivmecillinam | 56 993 | 1780 (3.1) | 2.63 (2.33–2.96) | 1.83 (1.62–2.08) | |
Clindamycin | 17 996 | 384 (2.1) | 1.76 (1.52–2.05) | 1.76 (1.51–2.05) | |
Penicillin V | 355 262 | 7142 (2.0) | 1.67 (1.49–1.87) | 1.50 (1.34–1.68) | |
Azitromycin | 9969 | 134 (1.3) | 1.12 (0.91–1.37) | 1.34 (1.09–1.64) | |
Doxycycline | 5000 | 65 (1.3) | 1.06 (0.81–1.38) | 1.33 (1.01–1.75) | |
Trim-sulpha | 14 964 | 210 (1.4) | 1.18 (0.99–1.41) | 1.26 (1.05–1.51) | |
Trimethoprim | 22 510 | 305 (1.4) | 1.13 (0.97–1.32) | 1.17 (0.99–1.37) | |
Cefalexin | 6 064 | 71 (1.2) | 0.97 (0.75–1.26) | 1.11 (0.86–1.44) | |
Nitrofurantoin | 24 499 | 435 (1.8) | 1.49 (1.28–1.72) | 0.61 (0.52–0.72) |
Multivariable models were also adjusted for the year the AB was dispensed. Only antibiotics with >5000 prescriptions are listed. Bold indicates P < 0.01.
AB, antibiotic; adjOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
Solids: characteristics associated with solid antibiotic formulations that were changed to a prescription with a different antibiotic or pharmaceutical characteristic from the Norwegian Prescription Database (NorPD) between 2004 and 2016
Solid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP) n = 694 516 . | Re-prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Solid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Pre-teen 10–12 years | 272 388 | 4156 (1.5) | Reference | Reference | Reference |
School 6–9 years | 313 042 | 6046 (1.9) | 1.28 (1.23–1.33) | 1.40 (1.35–1.46) | 1.38 (1.33–1.44) |
Preschool 4–5 years | 74 159 | 2856 (3.9) | 2.61 (2.49–2.74) | 3.06 (2.90–3.22) | 3.13 (2.98–3.29) |
Toddler 2–3 years | 26 107 | 2275 (8.7) | 6.25 (5.92–6.59) | 7.86 (7.43–8.33) | 8.25 (7.80–8.73) |
Infant 0–1 years | 8820 | 633 (7.2) | 5.18 (4.74–5.67) | 7.87 (7.16–8.66) | 8.81 (7.99–9.71) |
Girl | 380 566 | 8790 (2.3) | 1.01 (0.98–1.05) | 1.06 (1.03–1.10) | 1.06 (1.03–1.10) |
Reimbursed AB | 35 778 | 510 (1.4) | 0.62 (0.57–0.68) | 0.57 (0.52–0.63) | 0.68 (0.61–0.76) |
Prescriber | |||||
Specialist | |||||
None (ref) | 331 810 | 7935 (2.4) | Reference | Reference | Reference |
GP | 306 018 | 6980 (2.3) | 0.95 (0.92–0.99) | 1.05 (1.01–1.10) | 1.04 (1.00–1.08) |
Paediatrician | 26 286 | 524 (2.0) | 0.86 (0.79–0.94) | 0.96 (0.87–1.06) | 1.00 (0.91–1.11) |
Other | 30 402 | 527 (1.7) | 0.73 (0.66–0.79) | 0.84 (0.77–0.92) | 0.90 (0.82–0.99) |
Birth year | |||||
Before 1950 | 67 823 | 1291 (1.9) | Reference | Reference | Reference |
1950–59 | 192 050 | 4023 (2.1) | 1.10 (1.03–1.17) | 1.02 (0.96–1.09) | 1.02 (0.96–1.09) |
1960–69 | 172 782 | 3912 (2.3) | 1.19 (1.12–1.27) | 1.09 (1.02–1.16) | 1.08 (1.01–1.15) |
1970–79 | 184 484 | 4549 (2.5) | 1.30 (1.22–1.38) | 1.16 (1.09–1.25) | 1.15 (1.08–1.24) |
After 1980 | 77 011 | 2186 (2.8) | 1.49 (1.39–1.60) | 1.26 (1.16–1.37) | 1.25 (1.15–1.36) |
Female prescriber | 240 884 | 5660 (2.3) | 1.04 (1.00–1.07) | 0.98 (0.95–1.02) | 0.97 (0.94–1.01) |
AB Prescriptions per year (quart) | |||||
<23 | 208 436 | 4587 (2.2) | Reference | Reference | Reference |
24–42 | 174 434 | 4139 (2.4) | 1.08 (1.04–1.13) | 1.10 (1.05–1.15) | 1.08 (1.04–1.13) |
43–73 | 166 187 | 3965 (2.4) | 1.09 (1.04–1.14) | 1.15 (1.10–1.20) | 1.13 (1.08–1.19) |
>73 | 145 459 | 3275 (2.3) | 1.03 (0.98–1.08) | 1.14 (1.08–1.19) | 1.13 (1.07–1.18) |
Solid antibiotic | |||||
Shape | |||||
Round | 137 849 | 3023 (2.2) | Reference | Reference | |
Oval | 399 566 | 8090 (2.0) | 0.91 (0.88–0.95) | 1.32 (1.25–1.39) | |
Capsule | 157 101 | 4853 (3.1) | 1.40 (1.34–1.47) | 1.50 (1.41–1.60) | |
Scored | 418 047 | 7849 (1.9) | 0.63 (0.62–0.66) | 0.64 (0.60–0.67) | |
Size | |||||
20–<79 mm2 | 360 892 | 7898 (2.2) | Reference | Reference | |
79–124 mm2 | 281 419 | 6887 (2.4) | 1.12 (1.08–1.16) | 1.06 (1.00–1.11) | |
>124 mm2 | 52 205 | 1181 (2.3) | 1.04 (0.97–1.10) | 1.19 (1.10–1.28) | |
Antibiotic | |||||
Amoxicillin | 26 429 | 321 (1.2) | Reference | Reference | |
Erythromycin | 80 309 | 3102 (3.9) | 3.25 (2.90–3.65) | 3.92 (3.49–4.42) | |
Dicloxacillin | 55 097 | 1644 (3.0) | 2.50 (2.22–2.82) | 2.22 (1.96–2.51) | |
Clarithromycin | 8971 | 169 (1.9) | 1.56 (1.29–1.88) | 2.10 (1.74–2.54) | |
Pivmecillinam | 56 993 | 1780 (3.1) | 2.63 (2.33–2.96) | 1.83 (1.62–2.08) | |
Clindamycin | 17 996 | 384 (2.1) | 1.76 (1.52–2.05) | 1.76 (1.51–2.05) | |
Penicillin V | 355 262 | 7142 (2.0) | 1.67 (1.49–1.87) | 1.50 (1.34–1.68) | |
Azitromycin | 9969 | 134 (1.3) | 1.12 (0.91–1.37) | 1.34 (1.09–1.64) | |
Doxycycline | 5000 | 65 (1.3) | 1.06 (0.81–1.38) | 1.33 (1.01–1.75) | |
Trim-sulpha | 14 964 | 210 (1.4) | 1.18 (0.99–1.41) | 1.26 (1.05–1.51) | |
Trimethoprim | 22 510 | 305 (1.4) | 1.13 (0.97–1.32) | 1.17 (0.99–1.37) | |
Cefalexin | 6 064 | 71 (1.2) | 0.97 (0.75–1.26) | 1.11 (0.86–1.44) | |
Nitrofurantoin | 24 499 | 435 (1.8) | 1.49 (1.28–1.72) | 0.61 (0.52–0.72) |
Solid formulation . | |||||
---|---|---|---|---|---|
Characteristics . | Initial prescriptions (IP) n = 694 516 . | Re-prescriptions (% of IP) . | Univariable OR (95% CI) . | Model 1: Solid characteristics . | Model 2: Antibiotics . |
Multivariable adjOR: (95% CI) . | Multivariable adjOR: (95% CI) . | ||||
Child | |||||
Age group | |||||
Pre-teen 10–12 years | 272 388 | 4156 (1.5) | Reference | Reference | Reference |
School 6–9 years | 313 042 | 6046 (1.9) | 1.28 (1.23–1.33) | 1.40 (1.35–1.46) | 1.38 (1.33–1.44) |
Preschool 4–5 years | 74 159 | 2856 (3.9) | 2.61 (2.49–2.74) | 3.06 (2.90–3.22) | 3.13 (2.98–3.29) |
Toddler 2–3 years | 26 107 | 2275 (8.7) | 6.25 (5.92–6.59) | 7.86 (7.43–8.33) | 8.25 (7.80–8.73) |
Infant 0–1 years | 8820 | 633 (7.2) | 5.18 (4.74–5.67) | 7.87 (7.16–8.66) | 8.81 (7.99–9.71) |
Girl | 380 566 | 8790 (2.3) | 1.01 (0.98–1.05) | 1.06 (1.03–1.10) | 1.06 (1.03–1.10) |
Reimbursed AB | 35 778 | 510 (1.4) | 0.62 (0.57–0.68) | 0.57 (0.52–0.63) | 0.68 (0.61–0.76) |
Prescriber | |||||
Specialist | |||||
None (ref) | 331 810 | 7935 (2.4) | Reference | Reference | Reference |
GP | 306 018 | 6980 (2.3) | 0.95 (0.92–0.99) | 1.05 (1.01–1.10) | 1.04 (1.00–1.08) |
Paediatrician | 26 286 | 524 (2.0) | 0.86 (0.79–0.94) | 0.96 (0.87–1.06) | 1.00 (0.91–1.11) |
Other | 30 402 | 527 (1.7) | 0.73 (0.66–0.79) | 0.84 (0.77–0.92) | 0.90 (0.82–0.99) |
Birth year | |||||
Before 1950 | 67 823 | 1291 (1.9) | Reference | Reference | Reference |
1950–59 | 192 050 | 4023 (2.1) | 1.10 (1.03–1.17) | 1.02 (0.96–1.09) | 1.02 (0.96–1.09) |
1960–69 | 172 782 | 3912 (2.3) | 1.19 (1.12–1.27) | 1.09 (1.02–1.16) | 1.08 (1.01–1.15) |
1970–79 | 184 484 | 4549 (2.5) | 1.30 (1.22–1.38) | 1.16 (1.09–1.25) | 1.15 (1.08–1.24) |
After 1980 | 77 011 | 2186 (2.8) | 1.49 (1.39–1.60) | 1.26 (1.16–1.37) | 1.25 (1.15–1.36) |
Female prescriber | 240 884 | 5660 (2.3) | 1.04 (1.00–1.07) | 0.98 (0.95–1.02) | 0.97 (0.94–1.01) |
AB Prescriptions per year (quart) | |||||
<23 | 208 436 | 4587 (2.2) | Reference | Reference | Reference |
24–42 | 174 434 | 4139 (2.4) | 1.08 (1.04–1.13) | 1.10 (1.05–1.15) | 1.08 (1.04–1.13) |
43–73 | 166 187 | 3965 (2.4) | 1.09 (1.04–1.14) | 1.15 (1.10–1.20) | 1.13 (1.08–1.19) |
>73 | 145 459 | 3275 (2.3) | 1.03 (0.98–1.08) | 1.14 (1.08–1.19) | 1.13 (1.07–1.18) |
Solid antibiotic | |||||
Shape | |||||
Round | 137 849 | 3023 (2.2) | Reference | Reference | |
Oval | 399 566 | 8090 (2.0) | 0.91 (0.88–0.95) | 1.32 (1.25–1.39) | |
Capsule | 157 101 | 4853 (3.1) | 1.40 (1.34–1.47) | 1.50 (1.41–1.60) | |
Scored | 418 047 | 7849 (1.9) | 0.63 (0.62–0.66) | 0.64 (0.60–0.67) | |
Size | |||||
20–<79 mm2 | 360 892 | 7898 (2.2) | Reference | Reference | |
79–124 mm2 | 281 419 | 6887 (2.4) | 1.12 (1.08–1.16) | 1.06 (1.00–1.11) | |
>124 mm2 | 52 205 | 1181 (2.3) | 1.04 (0.97–1.10) | 1.19 (1.10–1.28) | |
Antibiotic | |||||
Amoxicillin | 26 429 | 321 (1.2) | Reference | Reference | |
Erythromycin | 80 309 | 3102 (3.9) | 3.25 (2.90–3.65) | 3.92 (3.49–4.42) | |
Dicloxacillin | 55 097 | 1644 (3.0) | 2.50 (2.22–2.82) | 2.22 (1.96–2.51) | |
Clarithromycin | 8971 | 169 (1.9) | 1.56 (1.29–1.88) | 2.10 (1.74–2.54) | |
Pivmecillinam | 56 993 | 1780 (3.1) | 2.63 (2.33–2.96) | 1.83 (1.62–2.08) | |
Clindamycin | 17 996 | 384 (2.1) | 1.76 (1.52–2.05) | 1.76 (1.51–2.05) | |
Penicillin V | 355 262 | 7142 (2.0) | 1.67 (1.49–1.87) | 1.50 (1.34–1.68) | |
Azitromycin | 9969 | 134 (1.3) | 1.12 (0.91–1.37) | 1.34 (1.09–1.64) | |
Doxycycline | 5000 | 65 (1.3) | 1.06 (0.81–1.38) | 1.33 (1.01–1.75) | |
Trim-sulpha | 14 964 | 210 (1.4) | 1.18 (0.99–1.41) | 1.26 (1.05–1.51) | |
Trimethoprim | 22 510 | 305 (1.4) | 1.13 (0.97–1.32) | 1.17 (0.99–1.37) | |
Cefalexin | 6 064 | 71 (1.2) | 0.97 (0.75–1.26) | 1.11 (0.86–1.44) | |
Nitrofurantoin | 24 499 | 435 (1.8) | 1.49 (1.28–1.72) | 0.61 (0.52–0.72) |
Multivariable models were also adjusted for the year the AB was dispensed. Only antibiotics with >5000 prescriptions are listed. Bold indicates P < 0.01.
AB, antibiotic; adjOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
Children below 4 years had almost eight times higher odds than pre-teens for changing a solid prescription. Prescriptions for both capsules and oval tablets were more strongly associated with prescription changes than round tablets (adjOR: 1.5 and 1.3, respectively), while scored tablets had a lower association (adjOR:0.6). There was also an influence of size, with extra-large solids having a stronger association with prescription changes (adjOR: 1.2) (Table 3).
Initial and subsequent antibiotic prescriptions
Of the initial prescriptions that were changed, penicillin V comprised the majority (58%) while amoxicillin was least commonly changed (6%) (Table 4). The macrolide/lincosamide group comprised most of the sequential prescriptions (36%). Of the initial macrolide/lincosamide antibiotics that were changed, 43% were followed by a subsequent prescription of a penicillin (penicillin V or amoxicillin).
Initial oral solid and liquid antibiotics and subsequent prescriptions with different antibiotics or pharmaceutical characteristics (e.g. taste, size, shape, or strength/concentration) from the Norwegian Prescription Database between 2004 and 2016
Initial prescription . | Subsequent prescription . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Penicillin V . | Macro/linco . | Amoxicillin . | Other . | Form . | |||||||
Antibiotic . | Form (n) . | Solid (6509) . | Liquid (10 707) . | Solid (4039) . | Liquid (16 946) . | Solid (790) . | Liquid (10 512) . | Solid (4062) . | Liquid (4835) . | Solid . | Liquid . |
PenV, 58% (33 967) | Solid (7142) | 2.3% (164) | 42.5% (3038) | 20.6% (1468) | 15.5% (1108) | 2.7% (196) | 9.5% (677) | 5.5% (395) | 1.3% (96) | 31.1% (2223) | 68.9% (4919) |
Liquid (26 825) | 17.9% (4813) | 18.2% (4873) | 0.8% (226) | 34.0% (9151) | 0.3% (76) | 24.6% (6601) | 0.5% (131) | 3.6% (954) | 19.6% (5246) | 80.4% (21 579) | |
Macro/linco, 21% (12 235) | Solid (3789) | 17.7% (669) | 3.6% (136) | 17.4% (661) | 34.1% (1291) | 5.8% (220) | 3.8% (144) | 15.8% (600) | 1.8% (68) | 56.7% (2150) | 43.3% (1639) |
Liquid (8446) | 6.7% (570) | 19.6% (1652) | 15.3% (1294) | 24.3% (2056) | 0.9% (72) | 20.7% (1749) | 2.9% (242) | 9.6% (811) | 25.8% (2178) | 74.2% (6268) | |
Amoxicillin, 6% (3550) | Solid (321) | 8.4% (27) | 2.5% (8) | 28.7% (92) | 10.9% (35) | 9.3% (30) | 20.9% (67) | 16.8% (54) | 2.5% (8) | 63.2% (203) | 36.8% (118) |
Liquid (3229) | 3.2% (103) | 13.4% (434) | 1.3% (42) | 53.4% (1725) | 3.4% (109) | 4.6% (149) | 4.1% (133) | 16.5% (534) | 12.0% (387) | 88.0 % (2842) | |
Other, 15% (8648) | Solid (4714) | 2.1% (100) | 4.7% (223) | 4.8% (228) | 19.6% (926) | 1.4% (66) | 8.7% (408) | 21.6% (1020) | 37.0% (1743) | 30.0% (1414) | 70.0% (3300) |
Liquid (3934) | 1.6% (63) | 8.7% (343) | 0.7% (28) | 16.6% (654) | 0.5% (21) | 18.2% (717) | 37.8% (1487) | 15.8% (621) | 40.6% (1599) | 59.4% (2335) | |
All formulations | Total (58 400) | Total penV 29.5% (17 216) | Total macro/linco 35.9% (20 985) | Total amoxicillin 19.4% (11 302) | Total other 15.2% (8897) | 26.4% (15 400) | 73.6% (43 000) |
Initial prescription . | Subsequent prescription . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Penicillin V . | Macro/linco . | Amoxicillin . | Other . | Form . | |||||||
Antibiotic . | Form (n) . | Solid (6509) . | Liquid (10 707) . | Solid (4039) . | Liquid (16 946) . | Solid (790) . | Liquid (10 512) . | Solid (4062) . | Liquid (4835) . | Solid . | Liquid . |
PenV, 58% (33 967) | Solid (7142) | 2.3% (164) | 42.5% (3038) | 20.6% (1468) | 15.5% (1108) | 2.7% (196) | 9.5% (677) | 5.5% (395) | 1.3% (96) | 31.1% (2223) | 68.9% (4919) |
Liquid (26 825) | 17.9% (4813) | 18.2% (4873) | 0.8% (226) | 34.0% (9151) | 0.3% (76) | 24.6% (6601) | 0.5% (131) | 3.6% (954) | 19.6% (5246) | 80.4% (21 579) | |
Macro/linco, 21% (12 235) | Solid (3789) | 17.7% (669) | 3.6% (136) | 17.4% (661) | 34.1% (1291) | 5.8% (220) | 3.8% (144) | 15.8% (600) | 1.8% (68) | 56.7% (2150) | 43.3% (1639) |
Liquid (8446) | 6.7% (570) | 19.6% (1652) | 15.3% (1294) | 24.3% (2056) | 0.9% (72) | 20.7% (1749) | 2.9% (242) | 9.6% (811) | 25.8% (2178) | 74.2% (6268) | |
Amoxicillin, 6% (3550) | Solid (321) | 8.4% (27) | 2.5% (8) | 28.7% (92) | 10.9% (35) | 9.3% (30) | 20.9% (67) | 16.8% (54) | 2.5% (8) | 63.2% (203) | 36.8% (118) |
Liquid (3229) | 3.2% (103) | 13.4% (434) | 1.3% (42) | 53.4% (1725) | 3.4% (109) | 4.6% (149) | 4.1% (133) | 16.5% (534) | 12.0% (387) | 88.0 % (2842) | |
Other, 15% (8648) | Solid (4714) | 2.1% (100) | 4.7% (223) | 4.8% (228) | 19.6% (926) | 1.4% (66) | 8.7% (408) | 21.6% (1020) | 37.0% (1743) | 30.0% (1414) | 70.0% (3300) |
Liquid (3934) | 1.6% (63) | 8.7% (343) | 0.7% (28) | 16.6% (654) | 0.5% (21) | 18.2% (717) | 37.8% (1487) | 15.8% (621) | 40.6% (1599) | 59.4% (2335) | |
All formulations | Total (58 400) | Total penV 29.5% (17 216) | Total macro/linco 35.9% (20 985) | Total amoxicillin 19.4% (11 302) | Total other 15.2% (8897) | 26.4% (15 400) | 73.6% (43 000) |
PenV, penicillin V; Macro/linco, macrolides/lincosamides.
Initial oral solid and liquid antibiotics and subsequent prescriptions with different antibiotics or pharmaceutical characteristics (e.g. taste, size, shape, or strength/concentration) from the Norwegian Prescription Database between 2004 and 2016
Initial prescription . | Subsequent prescription . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Penicillin V . | Macro/linco . | Amoxicillin . | Other . | Form . | |||||||
Antibiotic . | Form (n) . | Solid (6509) . | Liquid (10 707) . | Solid (4039) . | Liquid (16 946) . | Solid (790) . | Liquid (10 512) . | Solid (4062) . | Liquid (4835) . | Solid . | Liquid . |
PenV, 58% (33 967) | Solid (7142) | 2.3% (164) | 42.5% (3038) | 20.6% (1468) | 15.5% (1108) | 2.7% (196) | 9.5% (677) | 5.5% (395) | 1.3% (96) | 31.1% (2223) | 68.9% (4919) |
Liquid (26 825) | 17.9% (4813) | 18.2% (4873) | 0.8% (226) | 34.0% (9151) | 0.3% (76) | 24.6% (6601) | 0.5% (131) | 3.6% (954) | 19.6% (5246) | 80.4% (21 579) | |
Macro/linco, 21% (12 235) | Solid (3789) | 17.7% (669) | 3.6% (136) | 17.4% (661) | 34.1% (1291) | 5.8% (220) | 3.8% (144) | 15.8% (600) | 1.8% (68) | 56.7% (2150) | 43.3% (1639) |
Liquid (8446) | 6.7% (570) | 19.6% (1652) | 15.3% (1294) | 24.3% (2056) | 0.9% (72) | 20.7% (1749) | 2.9% (242) | 9.6% (811) | 25.8% (2178) | 74.2% (6268) | |
Amoxicillin, 6% (3550) | Solid (321) | 8.4% (27) | 2.5% (8) | 28.7% (92) | 10.9% (35) | 9.3% (30) | 20.9% (67) | 16.8% (54) | 2.5% (8) | 63.2% (203) | 36.8% (118) |
Liquid (3229) | 3.2% (103) | 13.4% (434) | 1.3% (42) | 53.4% (1725) | 3.4% (109) | 4.6% (149) | 4.1% (133) | 16.5% (534) | 12.0% (387) | 88.0 % (2842) | |
Other, 15% (8648) | Solid (4714) | 2.1% (100) | 4.7% (223) | 4.8% (228) | 19.6% (926) | 1.4% (66) | 8.7% (408) | 21.6% (1020) | 37.0% (1743) | 30.0% (1414) | 70.0% (3300) |
Liquid (3934) | 1.6% (63) | 8.7% (343) | 0.7% (28) | 16.6% (654) | 0.5% (21) | 18.2% (717) | 37.8% (1487) | 15.8% (621) | 40.6% (1599) | 59.4% (2335) | |
All formulations | Total (58 400) | Total penV 29.5% (17 216) | Total macro/linco 35.9% (20 985) | Total amoxicillin 19.4% (11 302) | Total other 15.2% (8897) | 26.4% (15 400) | 73.6% (43 000) |
Initial prescription . | Subsequent prescription . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Penicillin V . | Macro/linco . | Amoxicillin . | Other . | Form . | |||||||
Antibiotic . | Form (n) . | Solid (6509) . | Liquid (10 707) . | Solid (4039) . | Liquid (16 946) . | Solid (790) . | Liquid (10 512) . | Solid (4062) . | Liquid (4835) . | Solid . | Liquid . |
PenV, 58% (33 967) | Solid (7142) | 2.3% (164) | 42.5% (3038) | 20.6% (1468) | 15.5% (1108) | 2.7% (196) | 9.5% (677) | 5.5% (395) | 1.3% (96) | 31.1% (2223) | 68.9% (4919) |
Liquid (26 825) | 17.9% (4813) | 18.2% (4873) | 0.8% (226) | 34.0% (9151) | 0.3% (76) | 24.6% (6601) | 0.5% (131) | 3.6% (954) | 19.6% (5246) | 80.4% (21 579) | |
Macro/linco, 21% (12 235) | Solid (3789) | 17.7% (669) | 3.6% (136) | 17.4% (661) | 34.1% (1291) | 5.8% (220) | 3.8% (144) | 15.8% (600) | 1.8% (68) | 56.7% (2150) | 43.3% (1639) |
Liquid (8446) | 6.7% (570) | 19.6% (1652) | 15.3% (1294) | 24.3% (2056) | 0.9% (72) | 20.7% (1749) | 2.9% (242) | 9.6% (811) | 25.8% (2178) | 74.2% (6268) | |
Amoxicillin, 6% (3550) | Solid (321) | 8.4% (27) | 2.5% (8) | 28.7% (92) | 10.9% (35) | 9.3% (30) | 20.9% (67) | 16.8% (54) | 2.5% (8) | 63.2% (203) | 36.8% (118) |
Liquid (3229) | 3.2% (103) | 13.4% (434) | 1.3% (42) | 53.4% (1725) | 3.4% (109) | 4.6% (149) | 4.1% (133) | 16.5% (534) | 12.0% (387) | 88.0 % (2842) | |
Other, 15% (8648) | Solid (4714) | 2.1% (100) | 4.7% (223) | 4.8% (228) | 19.6% (926) | 1.4% (66) | 8.7% (408) | 21.6% (1020) | 37.0% (1743) | 30.0% (1414) | 70.0% (3300) |
Liquid (3934) | 1.6% (63) | 8.7% (343) | 0.7% (28) | 16.6% (654) | 0.5% (21) | 18.2% (717) | 37.8% (1487) | 15.8% (621) | 40.6% (1599) | 59.4% (2335) | |
All formulations | Total (58 400) | Total penV 29.5% (17 216) | Total macro/linco 35.9% (20 985) | Total amoxicillin 19.4% (11 302) | Total other 15.2% (8897) | 26.4% (15 400) | 73.6% (43 000) |
PenV, penicillin V; Macro/linco, macrolides/lincosamides.
The sensitivity analyses negligibly changed the results of the multivariable regressions (results not shown).
Discussion
Summary of the main findings
Requests for new prescriptions followed 3.0% of 2 691 483 initial antibiotic prescriptions for children. Young children who received solid formulations (10.9%) and certain poor-tasting antibiotics (8.6%) had the highest proportions of new prescriptions. Penicillin V was most commonly changed, while macrolides/lincosamides dominated subsequent prescriptions. In order of magnitude, the characteristics associated with requests for new prescriptions were as follows: the children’s ages (solids), poor taste and concentration of liquids, size and shape of solids, prescribers born in recent decades, and girl patients. Reimbursed prescriptions and scored solids were associated with fewer requests.
Comparison with existing literature
Changed antibiotic prescriptions represent situations of parents in great distress, unable to get their child to take the medicine prescribed to get well (4). In addition, changes from narrow- to broad-spectrum antibiotics may increase children’s short-term risk of side effects (6), and change of intestinal microbiome may result in future sequelae (27), furthering this distress. Changes also take parents’ time away from the sick child to contact the prescriber and pharmacy and increase treatment costs for extra antibiotic courses. Surprisingly, girls experienced more prescription changes than boys, which is not explained by significant body size differences (28). Boys were generally more positive than girls towards taking oral formulations of different types and sizes in a recent study, indicating possible gender differences (29). Giving toddlers medicine may be extra difficult, as their proportion of change was higher than other age groups. This may be related to the increased use of broad-spectrum antibiotics in this age group, putting them at risk of antibiotic resistance (30). One explanation may be that prescribers choose more acceptable medicines to save time, as 41% of our prescribers had issued a new prescription (25). Prescribers born in recent decades changed more prescriptions, which may have contributed to the increase in prescription changes over the last 13 years. This effect remained after adjusting for type of antibiotics and warrants further exploration.
Poor-tasting liquid antibiotics had 2.4 times higher odds of being changed than better-tasting liquids. This corresponds with findings that taste is a key characteristic associated with children’s refusal of medicines (31,32) and indicates that prescription changes can be used to identify antibiotics that are challenging for children to use. Changed prescriptions most likely underestimate administration challenges (4) and may contribute to the difference found in chronic children who were 3.8 times more likely to refuse poor-tasting medicines at least once (11). Taste may also explain why poor-tasting liquid penicillin V was most frequently replaced by better-tasting liquid amoxicillin and erythromycin, and even solid penicillin V that is easier to taste mask (33). Changes between liquid concentrations were seen for all the antibiotic groups. Concentrated liquids had 1.5 times greater odds of being changed, indicating that the advantage of having a smaller volume may not compensate for the stronger taste. The opposite was found in a study of children with chronic disease, although this was believed to be caused by an age factor (24).
There is little consensus in the literature regarding which size and shape solids to prescribe at different ages, but recent studies have shown that preschool children can swallow and even prefer mini tablets of 2–3 mm (34,35). There is a large discrepancy, though, between clinical studies and the availability of solids for clinical use (36). The two smallest solids in the dataset were 11 × 5 mm and 9 × 6.5 mm, which in a recent review would not be considered appropriate for children under 13 years (37). This is in keeping with the results in this study where younger children had stronger association with solid formulation changes, and medium and scored tablets had lower independent associations. Children can be taught to swallow solids (38), which may explain why this study showed that prescriptions reimbursed for children with a serious or chronic disease had lower odds for prescription changes.
Capsules had 1.5 times higher odds of prescription changes than round tablets, and erythromycin capsules were changed most frequently. This lack of preference for capsules may be explained by their large size and a misconception of being made from plastic (29). Erythromycin capsules, however, contain granules that can be sprinkled on food, making them easier to swallow (39), although this may not be known. Changes from penicillin V tablets to erythromycin were also seen (Table 4), which may indicate that opening the capsules may be known by some.
Strengths and limitations of the study
The strength of this study is the inclusion of prescriptions from the entire Norwegian paediatric population over a 13-year period. The two main limitations are lack of information regarding (i) the reason for requesting a new prescription and (ii) type and severity of infections. The prevalence of allergies and adverse effects is unknown and could contribute an overestimation of changes due to administration challenges. Though uncommon, more than one antibiotic could also have been prescribed on the same day intentionally, thus overestimating changes. Changes due to therapeutic failure could also overestimate the results, although the finding that more prescriptions were changed on Day 1 than on Day 2 indicates that this is unlikely to be a key factor.
Conclusion and implication
Changed prescriptions have costs for the involved children, their families and the health-care system in general. Narrow-spectrum antibiotics were changed more often than broad-spectrum antibiotics, indicating that costs related to children’s refusal and consequent antibiotic changes may contribute to the increased prescription rates of broad-spectrum antibiotics observed for young children in general. Advocating the development of more user-friendly formulations for children can therefore contribute to a more appropriate use of antibiotics in the paediatric population.
Declaration
Funding: this study was funded by a grant from the Liaison Committee between the Central Norway Regional Health Authority and Norwegian University of Science and Technology (NTNU).
Ethical approval: the study was approved by the Regional Committee for Medical and Health Research Ethics, Central Region, ref 2014/1743, and the Norwegian Prescription Database, ref 17/10581. Patient and prescriber personal identification numbers were pseudonymized by NorPD, allowing individual children’s prescriptions to be tracked over time without exposing their identities. The data were handled and stored anonymously.
Conflict of interest: none.
Acknowledgements
The authors would like to thank Eva Skovlund for support with the statistical analyses.